---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-007913"
form_type: "8-K"
ticker: "EDSA"
cik: "0001540159"
company_name: "Edesa Biotech, Inc."
filed_at: "2025-12-12T23:59:59+00:00"
generated_at: "2026-05-16T13:21:02.527548+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Edesa reports FY2025 net loss $7.2M; Phase 3 paridiprubart meets endpoints

## Summary
- Net loss $7.2M ($1.27/share) vs $6.2M ($1.93/share) prior year; OpEx $7.9M.
- Cash $10.8M at Sept 30, 2025; raised $3.4M net from ATM post-year-end.
- Phase 3 paridiprubart met primary/secondary endpoints; exploring partnerships.
- Initiated manufacturing for Phase 2 EB06 vitiligo study; recruitment mid-2026.
- Canadian gov't funding extended for respiratory program; JP Morgan meetings planned Jan 2026.

## SEC filing metadata
- accession: 0001171843-25-007913
- form_type: 8-K
- ticker: EDSA
- cik: 0001540159
- company_name: Edesa Biotech, Inc.
- filed_at: 2025-12-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1540159/000117184325007913/0001171843-25-007913-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1540159/000117184325007913/f8k_121125.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-007913
- JSON: https://secwatch.observer/filing/0001171843-25-007913.json
- Plain text: https://secwatch.observer/filing/0001171843-25-007913.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.